International Journal of Hematology

, Volume 98, Issue 6, pp 716–718

Improving cytopenia with splenic artery embolization in a patient with paroxysmal nocturnal hemoglobinuria on eculizumab

Authors

    • Department of Hematology/OncologySt-James University Hospital
  • Anita Hill
    • Department of Hematology/OncologySt-James University Hospital
  • Peter Hillmen
    • Department of Hematology/OncologySt-James University Hospital
  • Louise M. Arnold
    • Department of Hematology/OncologySt-James University Hospital
  • Gemma L. Brooksbank
    • Department of Hematology/OncologySt-James University Hospital
  • Alex Wood
    • Department of Hematology/OncologySt-James University Hospital
  • Andrew Scarsbrook
    • Department of RadiologySt-James University Hospital
  • Mervyn H. Davies
    • Department of HepatologySt-James University Hospital
  • Richard J. Kelly
    • Department of Hematology/OncologySt-James University Hospital
Case Report

DOI: 10.1007/s12185-013-1454-1

Cite this article as:
Krishnan, S.K., Hill, A., Hillmen, P. et al. Int J Hematol (2013) 98: 716. doi:10.1007/s12185-013-1454-1
  • 158 Views

Abstract

Paroxysmal nocturnal hemoglobinuria is a rare acquired stem cell disorder characterized by intravascular hemolysis, aplasia and an increased risk of thrombosis. We describe a patient under treatment with the anti-complement antibody eculizumab who developed pancytopenia, requiring blood transfusions, due to massive splenomegaly. The patient underwent two separate splenic embolizations, which reduced the size of the spleen and improved his blood count to the point that blood transfusions were no longer necessary. Splenic embolization was chosen over splenectomy due to the potential postoperative complications of splenectomy, especially that of thrombosis.

Keywords

Paroxysmal nocturnal hemoglobinuriaEculizumabSplenic artery embolizationCytopenia

Copyright information

© The Japanese Society of Hematology 2013